Get the Stockscreener App
1.785
0.83%
-0.015
Cabaletta Bio Inc stock is traded at $1.785, with a volume of 413.25K.
It is down -0.83% in the last 24 hours and up +35.23% over the past month.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
See More
Previous Close:
$1.80
Open:
$1.75
24h Volume:
413.25K
Relative Volume:
0.26
Market Cap:
$110.62M
Revenue:
-
Net Income/Loss:
$-67.68M
P/E Ratio:
-1.0753
EPS:
-1.66
Net Cash Flow:
$-54.24M
1W Performance:
-28.02%
1M Performance:
+35.23%
6M Performance:
-36.70%
1Y Performance:
-85.79%
1-Day Range:
$1.70
$1.795
1-Week Range:
$1.56
$2.59
52-Week Range:
$0.9857
$13.50
Cabaletta Bio Inc Stock (CABA) Company Profile
Name
Cabaletta Bio Inc
Sector
Industry
Phone
(267) 759-3100
Address
2929 ARCH STREET, PHILADELPHIA, PA
Compare CABA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
1.785 | 110.62M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.95 | 113.97B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
520.45 | 52.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
303.97 | 40.16B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
580.99 | 35.45B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
271.52 | 27.80B | 3.81B | -644.79M | -669.77M | -6.24 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-10-24 | Initiated | UBS | Buy |
| Feb-05-24 | Initiated | Jefferies | Buy |
| Nov-29-23 | Initiated | William Blair | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-19-23 | Initiated | Stifel | Buy |
| Sep-05-23 | Initiated | Citigroup | Buy |
| Jul-18-23 | Initiated | Guggenheim | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-30-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Jun-30-21 | Initiated | Mizuho | Buy |
| Jan-08-21 | Initiated | Chardan Capital Markets | Buy |
| Oct-13-20 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Initiated | Cowen | Outperform |
| Nov-19-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Morgan Stanley | Overweight |
View All
Cabaletta Bio Inc Stock (CABA) Latest News
Cabaletta Bio stock price target reiterated on strong clinical data By Investing.com - Investing.com India
Cabaletta Bio Prices Public Offering to Raise $100 Million - MSN
Cabaletta Bio Announces Public Offering of Common Stock and Warrants - MSN
Cabaletta Bio Reports Promising Data from RESET Trials for Transformative Autoimmune Therapy - MyChesCo
H.C. Wainwright reiterates buy rating on Cabaletta Bio stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates buy rating on Cabaletta Bio stock - Investing.com Australia
Cabaletta Bio’s (CABA) Buy Rating Reaffirmed at HC Wainwright - Defense World
Analysts Offer Predictions for Cabaletta Bio FY2026 Earnings - Defense World
Cabaletta Bio Launches Public Offering Of Stock And Warrants - Nasdaq
Cabaletta Bio (CABA) Shares Drop 20% After Public Offering Annou - GuruFocus
Cabaletta Bio prices $100 million public offering of shares and warrants By Investing.com - Investing.com South Africa
Cabaletta reports positive clinical data for autoimmune cell therapy By Investing.com - Investing.com South Africa
Cabaletta Bio looks to raise $100M in stock sale to fund cell therapy development - The Business Journals
Cabaletta Bio's (CABA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cabaletta Bio (CABA) Receives Reiterated Buy Rating from HC Wainwright & Co. | CABA Stock News - GuruFocus
Cabaletta Bio shares CAR-T results in three autoimmune conditions - Endpoints News
Cabaletta Bio Prices Securities Offering; Shares Fall - marketscreener.com
Cabaletta Bio stock tumbles after pricing $100 million public offering - Investing.com Australia
Cabaletta Bio Announces Pricing of Public Offering of Securities - GuruFocus
Cabaletta Bio prices $100 million public offering of shares and warrants - Investing.com
Cabaletta Bio: Sector Headwinds And Funding Issues, But Also Some Clear Clinical Direction - Seeking Alpha
Cantor Fitzgerald Predicts Cabaletta Bio FY2026 Earnings - MarketBeat
Cabaletta Bio announces public offering of common stock and warrants - Investing.com
Cabaletta Bio (CABA) Launches Public Offering with Warrants | CABA Stock News - GuruFocus
Cabaletta Bio (CABA) Showcases Promising Rese-cel Data at EULAR 2025 | CABA Stock News - GuruFocus
Cabaletta Bio Announces Proposed Public Offering of Securities | - GuruFocus
Cabaletta Bio Announces Proposed Public Offering of Securities - The Manila Times
Cabaletta Bio Announces Proposed Public Offering of Securities | CABA Stock News - GuruFocus
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress | CABA Stock News - GuruFocus
Autoimmune Disease Pioneer Cabaletta Bio Announces Major Public Offering With Jefferies Leading - Stock Titan
Cabaletta Bio Announces New Rese-cel Safety and Efficacy Data in Patients with Myositis, Lupus and Scleroderma to Be Presented at the EULAR 2025 Congress - The Manila Times
Cabaletta reports positive clinical data for autoimmune cell therapy - Investing.com
Breakthrough: New Autoimmune Therapy Achieves Drug-Free Remission in 94% of Trial Patients - Stock Titan
Cabaletta Bio Stockholders Approve Key Proposals - TipRanks
Squarepoint Ops LLC Cuts Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Millennium Management LLC Has $1.16 Million Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Wellington Management Group LLP Grows Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
CrowdStrike Stock Drops on Cautious Outlook -- Is This a Buying Opportunity? - The Globe and Mail
Two Sigma Investments LP Has $1.71 Million Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Bank of America Corp DE Buys 67,787 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Down 40% This Year, Is UnitedHealth Group's Dividend in Danger? - The Globe and Mail
Millennium Management LLC Sells 1,217,300 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Two Sigma Investments LP Boosts Stock Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Interactive Brokers Reports Y/Y Increase in May Client DARTs - The Globe and Mail
Two Sigma Advisers LP Buys 550,700 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
BNP Paribas Financial Markets Acquires Shares of 51,952 Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio to Present at Jefferies Global Healthcare Conference 2025 - MSN
Northern Trust Corp Sells 5,849 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio to Present at Jefferies Global Healthcare Conference on June 4, 2025 - Nasdaq
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Cabaletta Bio Showcases First-Ever Curative Autoimmune Cell Therapies at Major Jefferies Conference - Stock Titan
Cabaletta Bio Inc Stock (CABA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.06%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):